Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/60614
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSarana Boonbaichaiyaprucken_US
dc.contributor.authorSayan Cheepudomwiten_US
dc.contributor.authorPradit Panjaveninen_US
dc.contributor.authorTaworn Suthichaiyakulen_US
dc.contributor.authorWorachart Moleelerkpoomen_US
dc.contributor.authorThanawat Benjanuwatraen_US
dc.contributor.authorBancha Sukanandachaien_US
dc.contributor.authorAdisai Buakhamsrien_US
dc.date.accessioned2018-09-10T03:46:08Z-
dc.date.available2018-09-10T03:46:08Z-
dc.date.issued2008-08-01en_US
dc.identifier.issn01252208en_US
dc.identifier.issn01252208en_US
dc.identifier.other2-s2.0-50949101302en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=50949101302&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/60614-
dc.description.abstractBackground: LDL and hs-CRP are risk factors for vascular events and can be modified by Statin. Objective: To evaluate the baseline hs-CRP of a certain Thai population who would need Atorvastatin, to evaluate the dose response of Atorvastatin toward LDL and hs-CRP level, and to evaluate the efficacy and safety of different types of Atorvastatin. Material and Method: Subjects, who needed Statin therapy, were randomized to receive either 20 mg of Berlin (B)-Atorvastatin(R) or Pfizer(P)- Atorvastatin(R). The cross over took place after 8 weeks of therapy and continued for 16 weeks. Baseline blood tests were compared to 8 and 16 weeks. The effect of two brands of 20 mg Atorvastatin toward serum lipid, LFT, muscle enzyme and hs-CRP were compared. Results: One hundred and ten subjects aged between 20-75 years enrolled in the present study. Fifty-four and 56 patients were randomized to group A and B. Baseline total cholesterol, LDL, HDL, and TG were 251, 174, 55, and 160 mg/dl respectively. There was a wide variation of baseline hs-CRP level. One hundred and seven patients completed this 16 weeks study. Atorvastatin 20 mg lowered TC by 32%, LDL 44% and hs-CRP 10% at 16 weeks for the entire study (p < 0.003). The effect of either Atorvastatin the lipid profiles and hs-CRP were different. There was no significant change in LFT or muscle enzyme. Conclusion: Atorvastatin 20 mg has a dramatic effect on the lipid but moderate effect on CRP. The two different types of Atorvastatin (group A and B) have similar effect on both safety and efficacy.en_US
dc.subjectMedicineen_US
dc.titleEffect of Atorvastatin on LDL &amp; hs-CRP in a selected Thai populationen_US
dc.typeJournalen_US
article.title.sourcetitleJournal of the Medical Association of Thailanden_US
article.volume91en_US
article.stream.affiliationsMahidol Universityen_US
article.stream.affiliationsKing Chulalongkorn Memorial Hospital, Faculty of Medicine Chulalongkorn Universityen_US
article.stream.affiliationsPolice General Hospitalen_US
article.stream.affiliationsChiang Mai Universityen_US
article.stream.affiliationsMaharat Nakhon Si Thammarat Hospitalen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.